Condition guide · 9 min read

Diabetic retinopathy — supplement adjuncts and what to skip

Updated 2026-05-20 · Reviewed by SupplementScore editors · No sponsorships

Diabetic retinopathy is a microvascular complication of long-standing diabetes and a leading cause of preventable adult blindness worldwide. The decisive interventions are glycaemic control (HbA1c), blood-pressure control, statin therapy where indicated, and timely ophthalmologic care (laser, intravitreal anti-VEGF, or vitrectomy). Supplements are adjunctive at best. Below is what has credible evidence — and the much longer list of products that look good in marketing copy but have nothing in the trial record.

This is adjunctive, not curative. Diabetic retinopathy progression is driven by glycaemic and blood-pressure control. No supplement reverses established proliferative retinopathy or substitutes for laser, anti-VEGF, or surgery. Annual dilated eye exams (or more often if disease present) are non-negotiable.

Supplements with credible adjunctive evidence

Tier 2 · Macular pigment optical density

Lutein + zeaxanthin

Lutein 10 mg + zeaxanthin 2 mg daily

Lutein and zeaxanthin concentrate in the macula and act as filters of high-energy short-wavelength light. The LUTEGA trial and the 2020 Hu meta-analysis show modest improvements in visual function, contrast sensitivity, and macular pigment optical density in non-proliferative diabetic retinopathy. The effect on disease progression is less clear; the visual-function effect is modest but real. Use the AREDS2-style dose. Pair with adequate dietary intake (leafy greens, egg yolks).

Tier 2 · Antioxidant adjunct in diabetic neuropathy and microvascular disease

Alpha-lipoic acid

600 mg/day, with food

Alpha-lipoic acid has more evidence for diabetic peripheral neuropathy than for retinopathy specifically, but some small trials and animal models suggest a microvascular protective effect that extends to the retina. The 2020 Haupt and 2022 Saboori-style meta-analyses show modest improvement in endothelial function in diabetic patients. Consider it as a microvascular-friendly adjunct in patients who also have neuropathic symptoms.

Tier 1 · Foundational cardiometabolic support

Omega-3 (EPA/DHA)

1–2 g combined EPA + DHA daily

The PREDIMED secondary analysis found higher omega-3 intake associated with reduced incidence of sight-threatening diabetic retinopathy in older Spanish adults with type 2 diabetes. Effect size is modest and the design is observational-within-RCT, but the foundational cardiometabolic role of omega-3 (triglycerides, cardiovascular events) gives it a place in nearly every type-2-diabetes adjunct stack. Choose a third-party-tested EPA/DHA product.

Tier 1 · Common deficiency in diabetic populations

Vitamin D3

1000–2000 IU/day, titrated to 25-OH-D 30–50 ng/mL

Vitamin D deficiency is more common in people with diabetes, and lower 25-OH-D is associated with more advanced retinopathy in cross-sectional studies. The randomised-trial evidence for reversing retinopathy is thin, but deficiency correction is reasonable on broader grounds (bone, immune, possible cardiovascular). Test before supplementing to target 30–50 ng/mL; routine "high-dose" empirical dosing is not appropriate.

Tier 3 · Mechanism-based but trial evidence thin in retinopathy

Benfotiamine

300–600 mg/day in divided doses

A lipid-soluble derivative of thiamine that achieves higher tissue levels than thiamine HCl and is theorised to reduce advanced-glycation-endproduct formation. The neuropathy trial signal is modest but reproducible; the retinopathy trial base is much thinner. A reasonable adjunct in patients who also have diabetic peripheral neuropathy. Not a replacement for any standard care.

What to skip

Practical priority list. Glycaemic control (HbA1c <7% individualised), blood pressure (typically <130/80), statin where indicated, and annual or more frequent dilated eye exams. Supplements ranked: omega-3 EPA/DHA → vitamin D3 if deficient → lutein/zeaxanthin → alpha-lipoic acid (if neuropathy) → benfotiamine (if neuropathy). Anti-VEGF, laser, and surgery as decided by your ophthalmologist.

What to discuss with your ophthalmologist

Any supplement that affects platelet function or anticoagulation (high-dose omega-3, ginkgo, vitamin E, fish oil) should be flagged before intravitreal injections or vitrectomy. Patients on warfarin should not start ALA without monitoring. Vitamin K-containing multivitamins matter in patients on warfarin.

Sources

Read more: